Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS)
Status: Enrolling
Updated:  4/28/2014
Clinical Research Facility
mi
from
Boston, MA
Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS)
Status: Enrolling
Updated: 4/28/2014
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS)
Status: Enrolling
Updated:  4/28/2014
Clinical Research Facility
mi
from
Ann Arbor, MI
Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS)
Status: Enrolling
Updated: 4/28/2014
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS)
Status: Enrolling
Updated:  4/28/2014
Clinical Research Facility
mi
from
Hackensack, NJ
Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS)
Status: Enrolling
Updated: 4/28/2014
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS)
Status: Enrolling
Updated:  4/28/2014
Clinical Research Facility
mi
from
Nashville, TN
Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS)
Status: Enrolling
Updated: 4/28/2014
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Free Fatty Acid Metabolite Biomarkers for Cancer
Status: Enrolling
Updated:  5/14/2014
Cleveland Clinic
mi
from
Cleveland, OH
Free Fatty Acid Metabolite Biomarkers for Cancer
Status: Enrolling
Updated: 5/14/2014
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Status: Enrolling
Updated:  5/14/2014
Kaiser Permanente Los Angeles (Sunset)
mi
from
Los Angeles, CA
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Status: Enrolling
Updated: 5/14/2014
Kaiser Permanente Los Angeles (Sunset)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Status: Enrolling
Updated:  5/14/2014
Kaiser Permanente Riverside
mi
from
Riverside, CA
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy
Status: Enrolling
Updated: 5/14/2014
Kaiser Permanente Riverside
mi
from
Riverside, CA
Click here to add this to my saved trials
Improving Energy Balance in Men With Prostate Cancer
Exploring the Impact of Negative Energy Balance in Men With Prostate Cancer
Status: Enrolling
Updated:  7/7/2014
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Improving Energy Balance in Men With Prostate Cancer
Exploring the Impact of Negative Energy Balance in Men With Prostate Cancer
Status: Enrolling
Updated: 7/7/2014
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Click here to add this to my saved trials
Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer
Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer
Status: Enrolling
Updated:  12/3/2014
University of California, Irvine Health
mi
from
Orange, CA
Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer
Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer
Status: Enrolling
Updated: 12/3/2014
University of California, Irvine Health
mi
from
Orange, CA
Click here to add this to my saved trials
A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer
A Pilot Clinical Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer by Molecular Imaging of VEGFR2
Status: Enrolling
Updated:  3/17/2015
Stanford University Medical Center
mi
from
Palo Alto, CA
A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer
A Pilot Clinical Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer by Molecular Imaging of VEGFR2
Status: Enrolling
Updated: 3/17/2015
Stanford University Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer
68Ga-PSMA (ProstaMedix™) PET-CT Scan for Diagnosis and Management of Prostate Cancer
Status: Enrolling
Updated:  4/13/2015
Radio- Isotope Therapy of America
mi
from
Houston, TX
68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer
68Ga-PSMA (ProstaMedix™) PET-CT Scan for Diagnosis and Management of Prostate Cancer
Status: Enrolling
Updated: 4/13/2015
Radio- Isotope Therapy of America
mi
from
Houston, TX
Click here to add this to my saved trials
68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer
68Ga-PSMA (ProstaMedix™) PET-CT Scan for Diagnosis and Management of Prostate Cancer
Status: Enrolling
Updated:  4/13/2015
Radio- Isotope Therapy of America
mi
from
Houston, TX
68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer
68Ga-PSMA (ProstaMedix™) PET-CT Scan for Diagnosis and Management of Prostate Cancer
Status: Enrolling
Updated: 4/13/2015
Radio- Isotope Therapy of America
mi
from
Houston, TX
Click here to add this to my saved trials
68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer
68Ga-PSMA (ProstaMedix™) PET-CT Scan for Diagnosis and Management of Prostate Cancer
Status: Enrolling
Updated:  4/13/2015
RITA Foundation
mi
from
Houston, TX
68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer
68Ga-PSMA (ProstaMedix™) PET-CT Scan for Diagnosis and Management of Prostate Cancer
Status: Enrolling
Updated: 4/13/2015
RITA Foundation
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer
A Phase 2 Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer
Status: Enrolling
Updated:  4/22/2015
Washington University
mi
from
St Louis, MO
A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer
A Phase 2 Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer
Status: Enrolling
Updated: 4/22/2015
Washington University
mi
from
St Louis, MO
Click here to add this to my saved trials
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/5/2015
Mayo Clinic Cancer Center
mi
from
Scottsdale, AZ
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/5/2015
Mayo Clinic Cancer Center
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/5/2015
Premiere Oncology of Arizona
mi
from
Scottsdale, AZ
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/5/2015
Premiere Oncology of Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/5/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/5/2015
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/5/2015
LSU Health Sciences Center
mi
from
Shreveport, LA
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/5/2015
LSU Health Sciences Center
mi
from
Shreveport, LA
Click here to add this to my saved trials
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/5/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/5/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/5/2015
The Mayo Clinic
mi
from
Rochester, MN
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/5/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/5/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/5/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/5/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/5/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/5/2015
UT Health and Science Center
mi
from
San Antonio, TX
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/5/2015
UT Health and Science Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/5/2015
Northwest Medical Specialties
mi
from
Tacoma, WA
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/5/2015
Northwest Medical Specialties
mi
from
Tacoma, WA
Click here to add this to my saved trials
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  5/5/2015
University of Wisconsin
mi
from
Madison, WI
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 5/5/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  7/3/2015
Clinical Research Facility
mi
from
San Francisco, CA
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 7/3/2015
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  7/3/2015
Clinical Research Facility
mi
from
Evanston, IL
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 7/3/2015
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  7/3/2015
Clinical Research Facility
mi
from
Baltimore, MD
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 7/3/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  7/3/2015
Clinical Research Facility
mi
from
Boston, MA
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 7/3/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  7/3/2015
Clinical Research Facility
mi
from
New York, NY
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 7/3/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  7/3/2015
Clinical Research Facility
mi
from
Seattle, WA
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 7/3/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  7/3/2015
mi
from
Villejuif,
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 7/3/2015
mi
from
Villejuif,
Click here to add this to my saved trials
Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
A Randomized Study of Lapatinib With Radiation Versus Radiation Alone in Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
Status: Enrolling
Updated:  7/6/2015
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
A Randomized Study of Lapatinib With Radiation Versus Radiation Alone in Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
Status: Enrolling
Updated: 7/6/2015
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
A Randomized Study of Lapatinib With Radiation Versus Radiation Alone in Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
Status: Enrolling
Updated:  7/6/2015
Massey Cancer Center, Virginia Commonwealth University
mi
from
Richmond, VA
Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
A Randomized Study of Lapatinib With Radiation Versus Radiation Alone in Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
Status: Enrolling
Updated: 7/6/2015
Massey Cancer Center, Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
Veterans Affairs Medical Center - Birmingham
mi
from
Birmingham, AL
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
Veterans Affairs Medical Center - Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
University of California San Diego Cancer Center
mi
from
La Jolla, CA
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
University of California San Diego Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
UCSF Cancer Center and Cancer Research Institute
mi
from
San Francisco, CA
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
UCSF Cancer Center and Cancer Research Institute
mi
from
San Francisco, CA
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
Veterans Affairs Medical Center - San Francisco
mi
from
San Francisco, CA
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
Veterans Affairs Medical Center - San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Christiana Care Health Services
mi
from
Wilmington, DE
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Christiana Care Health Services
mi
from
Wilmington, DE
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
Vincent T. Lombardi Cancer Research Center, Georgetown University
mi
from
Washington,
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
Vincent T. Lombardi Cancer Research Center, Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
Walter Reed Army Medical Center
mi
from
Washington,
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
Walter Reed Army Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
University of Illinois at Chicago Health Sciences Center
mi
from
Chicago, IL
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
University of Illinois at Chicago Health Sciences Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
Veterans Affairs Medical Center - Chicago Westside Hospital
mi
from
Chicago, IL
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
Veterans Affairs Medical Center - Chicago Westside Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
Veterans Affairs Medical Center - Togus
mi
from
Togus, ME
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
Veterans Affairs Medical Center - Togus
mi
from
Togus, ME
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
mi
from
Baltimore, MD
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated:  7/7/2015
University of Massachusetts Memorial Medical Center
mi
from
Worcester, MA
Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Androgen Receptor Mutations in Hormone Refractory Prostate Cancer
Status: Enrolling
Updated: 7/7/2015
University of Massachusetts Memorial Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials